{"version":"https://jsonfeed.org/version/1.1","title":"openbell | Financial news scored by AI. No noise, no delay.","description":"OpenBell scores breaking market news for potential price impact, so you can see why it matters, not just that it happened.","home_page_url":"http://www.openbell.ai","feed_url":"http://www.openbell.ai/feed.json","language":"en","icon":"http://www.openbell.ai/favicon.ico","favicon":"http://www.openbell.ai/favicon.ico","items":[{"id":"NNVC:1791895695158","url":"http://www.openbell.ai/news/NNVC:1791895695158","title":"NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well","content_text":"NanoViricides is currently conducting a Phase IIA clinical trial for its NV-387 oral gummies aimed at treating the Ebola Bundibugyo virus in the Democratic Republic of Congo. The trial is assessing different dosage regimens for patients with varying severity levels of the disease, primarily focusing on those in the 'Wet Stage' with severe symptoms. The trial will evaluate the safety and tolerability of the treatment, with results expected to indicate whether NV-387 can progress to Phase IIB based on its safety profile and potential efficacy against the high infection-to-fatality rate of 67-75% observed in the region.","summary":"NanoViricides is currently conducting a Phase IIA clinical trial for its NV-387 oral gummies aimed at treating the Ebola Bundibugyo virus in the Democratic Republic of Congo. The trial is assessing different dosage regimens for patients with varying severity levels of the disease, primarily focusing on those in the 'Wet Stage' with severe symptoms. The trial will evaluate the safety and tolerability of the treatment, with results expected to indicate whether NV-387 can progress to Phase IIB based on its safety profile and potential efficacy against the high infection-to-fatality rate of 67-75% observed in the region.","date_published":"2026-10-13T12:48:15.158Z","date_modified":"2026-10-13T12:48:15.158Z","author":{"name":"Benzinga Newsdesk"},"tags":["Healthcare","NNVC","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Healthcare","ticker":"NNVC","original_url":"https://www.benzinga.com/news/26/10/62321991/nanoviricides-says-its-phase-iia-ebola-treatment-clinical-trial-nv-387-oral-gummies-progressing-well"},"image":"https://cdn.brandfetch.io/NNVC/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"WDAY:1791895655542","url":"http://www.openbell.ai/news/WDAY:1791895655542","title":"Workday To Acquire C1.ai To Strengthen Identity Governance And Secure Access For Employees And AI Agents; No Financial Terms Disclosed","content_text":"Workday, Inc. has signed a definitive agreement to acquire C1.ai, a platform specializing in identity governance for employees and AI agents. This acquisition aims to enhance Workday's capabilities in managing access across various business systems, addressing the challenges posed by the increasing use of autonomous agents. Financial terms of the deal were not disclosed, but the integration is expected to streamline access management from the point of hiring to departure, ensuring security and compliance.","summary":"Workday, Inc. has signed a definitive agreement to acquire C1.ai, a platform specializing in identity governance for employees and AI agents. This acquisition aims to enhance Workday's capabilities in managing access across various business systems, addressing the challenges posed by the increasing use of autonomous agents. Financial terms of the deal were not disclosed, but the integration is expected to streamline access management from the point of hiring to departure, ensuring security and compliance.","date_published":"2026-10-13T12:47:35.542Z","date_modified":"2026-10-13T12:47:35.542Z","author":{"name":"Benzinga Newsdesk"},"tags":["Technology","WDAY","AI Analysis","Impact: 75"],"_openbell":{"impact_score":75,"sector":"Technology","ticker":"WDAY","original_url":"https://www.benzinga.com/m/26/10/62321973/workday-acquire-c1-ai-strengthen-identity-governance-and-secure-access-employees-and-ai-agents-no-fi"},"image":"https://cdn.brandfetch.io/WDAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"CIFR:1791895626991","url":"http://www.openbell.ai/news/CIFR:1791895626991","title":"Cipher Digital Stock Falls After Proposing $850 Million in Notes. Here’s Where the Money Would Go","content_text":"Cipher Digital Inc. (NASDAQ: CIFR) announced a proposed private offering of $850 million in 0.00% convertible senior notes due 2032, which has led to a 12.47% drop in its stock price, currently trading at $11.38. The company plans to use the proceeds for capped call transactions, investment in the Barber Lake project, and expanding its high-performance computing strategy. Additionally, Cipher intends to exchange part of its 1.75% convertible senior notes due 2030 for shares of common stock, which may impact share price due to associated trading activities.","summary":"Cipher Digital Inc. (NASDAQ: CIFR) announced a proposed private offering of $850 million in 0.00% convertible senior notes due 2032, which has led to a 12.47% drop in its stock price, currently trading at $11.38. The company plans to use the proceeds for capped call transactions, investment in the Barber Lake project, and expanding its high-performance computing strategy. Additionally, Cipher intends to exchange part of its 1.75% convertible senior notes due 2030 for shares of common stock, which may impact share price due to associated trading activities.","date_published":"2026-10-13T12:47:06.991Z","date_modified":"2026-10-13T12:47:06.991Z","author":{"name":"Dylan Berman"},"tags":["Technology","CIFR","AI Analysis","Impact: -75"],"_openbell":{"impact_score":-75,"sector":"Technology","ticker":"CIFR","original_url":"https://www.benzinga.com/trading-ideas/movers/26/10/62321952/cipher-digital-stock-falls-after-proposing-850-million-in-notes-heres-where-the-money-would-go"},"image":"https://cdn.brandfetch.io/CIFR/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"BTC:1791895477318","url":"http://www.openbell.ai/news/BTC:1791895477318","title":"Tokenized Real-World Assets Reach $39B With Only Two Dominant Players","content_text":"Tokenized real-world assets (RWA) have surged to approximately $39 billion as of October 9, 2026, marking an 81% growth from $21.5 billion at the beginning of the year. Stellar and BNB Chain are the dominant players, contributing 38% and 24% of the growth, respectively. The market cap for RWAs is estimated at $46.8 billion, with around 6.1 million holders, reflecting a 42% increase in holders from early September to early October. Despite fluctuations in trading volumes, traditional financial institutions are increasingly adopting blockchain technology for tokenization.","summary":"Tokenized real-world assets (RWA) have surged to approximately $39 billion as of October 9, 2026, marking an 81% growth from $21.5 billion at the beginning of the year. Stellar and BNB Chain are the dominant players, contributing 38% and 24% of the growth, respectively. The market cap for RWAs is estimated at $46.8 billion, with around 6.1 million holders, reflecting a 42% increase in holders from early September to early October. Despite fluctuations in trading volumes, traditional financial institutions are increasingly adopting blockchain technology for tokenization.","date_published":"2026-10-13T12:44:37.318Z","date_modified":"2026-10-13T12:44:37.318Z","author":{"name":"Kenneth Rapoza"},"tags":["Financial Services","BTC","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Financial Services","ticker":"BTC","original_url":"https://www.benzinga.com/Opinion/26/10/62321906/tokenized-real-world-assets-reach-39b-with-only-two-dominant-players"},"image":"https://cdn.brandfetch.io/BTC/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"HLF:1791895446791","url":"http://www.openbell.ai/news/HLF:1791895446791","title":"Top 3 Risk Off Stocks You May Want To Dump In Q4","content_text":"As of October 13, 2026, three consumer staples stocks are identified as potentially risky for investors focusing on momentum: Herbalife Ltd (HLF), Utz Brands Inc (UTZ), and BBB Foods Inc (TBBB). Herbalife announced a $250 million share repurchase program, with shares gaining 4.5% to close at $13.61, and an RSI of 74.3. Utz Brands declared a quarterly cash dividend, with shares closing at $14.30 and an RSI of 71.5, while BBB Foods reported better-than-expected sales, closing at $56.30 with an RSI of 71.9.","summary":"As of October 13, 2026, three consumer staples stocks are identified as potentially risky for investors focusing on momentum: Herbalife Ltd (HLF), Utz Brands Inc (UTZ), and BBB Foods Inc (TBBB). Herbalife announced a $250 million share repurchase program, with shares gaining 4.5% to close at $13.61, and an RSI of 74.3. Utz Brands declared a quarterly cash dividend, with shares closing at $14.30 and an RSI of 71.5, while BBB Foods reported better-than-expected sales, closing at $56.30 with an RSI of 71.9.","date_published":"2026-10-13T12:44:06.791Z","date_modified":"2026-10-13T12:44:06.791Z","author":{"name":"Avi Kapoor"},"tags":["Consumer Defensive","HLF","AI Analysis","Impact: -60"],"_openbell":{"impact_score":-60,"sector":"Consumer Defensive","ticker":"HLF","original_url":"https://www.benzinga.com/trading-ideas/short-ideas/26/10/62321881/top-3-risk-off-stocks-you-may-want-to-dump-in-q4"},"image":"https://cdn.brandfetch.io/HLF/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"SPY:1791895373012","url":"http://www.openbell.ai/news/SPY:1791895373012","title":"Redbook Retail Sales Index Up 10.4% YoY For Week Ended 10/10/26","content_text":"","summary":"","date_published":"2026-10-13T12:42:53.012Z","date_modified":"2026-10-13T12:42:53.012Z","author":{"name":"Benzinga Newsdesk"},"tags":["Financial Services","SPY","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Financial Services","ticker":"SPY","original_url":"https://www.benzinga.com/economics/macro-economic-events/26/10/62321839/redbook-retail-sales-index-10-4-yoy-week-ended-10-10-26"},"image":"https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"ACI:1791895357226","url":"http://www.openbell.ai/news/ACI:1791895357226","title":"Albertsons Exec Says Co. Must Move Faster To Reduce Costs; Reinvest Much Of Those Savings Into Lower Prices; Improve Store Experience","content_text":"During a recent conference call, an executive from Albertsons emphasized the need for the company to accelerate its cost-reduction efforts. The strategy involves reinvesting a significant portion of the savings into lowering prices for customers and enhancing the overall store experience. This approach aims to improve competitiveness in the grocery market.","summary":"During a recent conference call, an executive from Albertsons emphasized the need for the company to accelerate its cost-reduction efforts. The strategy involves reinvesting a significant portion of the savings into lowering prices for customers and enhancing the overall store experience. This approach aims to improve competitiveness in the grocery market.","date_published":"2026-10-13T12:42:37.226Z","date_modified":"2026-10-13T12:42:37.226Z","author":{"name":"Benzinga Newsdesk"},"tags":["Consumer Defensive","ACI","AI Analysis","Impact: 50"],"_openbell":{"impact_score":50,"sector":"Consumer Defensive","ticker":"ACI","original_url":"https://www.benzinga.com/news/26/10/62321820/albertsons-exec-says-co-must-move-faster-reduce-costs-reinvest-much-those-savings-lower-prices-impro"},"image":"https://cdn.brandfetch.io/ACI/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"META:1791895345587","url":"http://www.openbell.ai/news/META:1791895345587","title":"Truist Securities Maintains Buy on Meta Platforms, Raises Price Target to $1000","content_text":"Truist Securities analyst Youssef Squali has reaffirmed a Buy rating on Meta Platforms (NASDAQ: META) and increased the price target from $763 to $1000. This adjustment reflects a positive outlook on the company's performance and potential growth.","summary":"Truist Securities analyst Youssef Squali has reaffirmed a Buy rating on Meta Platforms (NASDAQ: META) and increased the price target from $763 to $1000. This adjustment reflects a positive outlook on the company's performance and potential growth.","date_published":"2026-10-13T12:42:25.587Z","date_modified":"2026-10-13T12:42:25.587Z","author":{"name":"Benzinga Newsdesk"},"tags":["Communication Services","META","AI Analysis","Impact: 85"],"_openbell":{"impact_score":85,"sector":"Communication Services","ticker":"META","original_url":"https://www.benzinga.com/news/26/10/62321811/truist-securities-maintains-buy-meta-platforms-raises-price-target-1000"},"image":"https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"USO:1791895328730","url":"http://www.openbell.ai/news/USO:1791895328730","title":"Yemen's Houthis Warn Employees And Civilians To Evacuate Areas Near Aramco Oil Facilities, Say They Are Legitimate Targets","content_text":"The Houthis have issued a warning to employees and civilians to evacuate areas near Aramco oil facilities, declaring them legitimate targets. This announcement comes amidst ongoing military tensions in the region. The potential threat to oil infrastructure could impact global oil supply and prices.","summary":"The Houthis have issued a warning to employees and civilians to evacuate areas near Aramco oil facilities, declaring them legitimate targets. This announcement comes amidst ongoing military tensions in the region. The potential threat to oil infrastructure could impact global oil supply and prices.","date_published":"2026-10-13T12:42:08.730Z","date_modified":"2026-10-13T12:42:08.730Z","author":{"name":"Benzinga Newsdesk"},"tags":["Financial Services","USO","AI Analysis","Impact: -70"],"_openbell":{"impact_score":-70,"sector":"Financial Services","ticker":"USO","original_url":"https://www.benzinga.com/economics/macro-economic-events/26/10/62321793/yemen-s-houthis-warn-employees-and-civilians-evacuate-areas-near-aramco-oil-facilities-say-they-are-"},"image":"https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"TSLA:1791895319510","url":"http://www.openbell.ai/news/TSLA:1791895319510","title":"Goldman Says Tesla’s Robotaxi, Optimus Outlook Will Matter More Than Q3 Earnings. Here’s the Bar for Oct. 21","content_text":"Tesla Inc. (NASDAQ: TSLA) is set to report its third-quarter earnings on October 21, with analysts estimating earnings per share of 43 cents and revenue of $27.90 billion. The company delivered 486,532 vehicles in the third quarter, surpassing estimates, but investors are more focused on updates regarding Full Self-Driving, robotaxi, and Optimus, which Goldman Sachs indicates may have a greater impact on the stock than earnings. Currently, Tesla shares are trading at $374.53, approximately 3.9% below its 200-day moving average.","summary":"Tesla Inc. (NASDAQ: TSLA) is set to report its third-quarter earnings on October 21, with analysts estimating earnings per share of 43 cents and revenue of $27.90 billion. The company delivered 486,532 vehicles in the third quarter, surpassing estimates, but investors are more focused on updates regarding Full Self-Driving, robotaxi, and Optimus, which Goldman Sachs indicates may have a greater impact on the stock than earnings. Currently, Tesla shares are trading at $374.53, approximately 3.9% below its 200-day moving average.","date_published":"2026-10-13T12:41:59.510Z","date_modified":"2026-10-13T12:41:59.510Z","author":{"name":"Dylan Berman"},"tags":["Consumer Cyclical","TSLA","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Consumer Cyclical","ticker":"TSLA","original_url":"https://www.benzinga.com/trading-ideas/movers/26/10/62321790/goldman-says-teslas-robotaxi-optimus-outlook-will-matter-more-than-q3-earnings-heres-the-bar-for-oct-21"},"image":"https://cdn.brandfetch.io/TSLA/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"BMBL:1791895200842","url":"http://www.openbell.ai/news/BMBL:1791895200842","title":"Trading Halt: Halt status updated at 8:40:00 AM ET: Quotation Resumption: News and Resumption Times","content_text":"","summary":"","date_published":"2026-10-13T12:40:00.842Z","date_modified":"2026-10-13T12:40:00.842Z","author":{"name":"Benzinga Newsdesk"},"tags":["Communication Services","BMBL","AI Analysis","Impact: -50"],"_openbell":{"impact_score":-50,"sector":"Communication Services","ticker":"BMBL","original_url":"https://www.benzinga.com/content/62321738/trading-halt-halt-status-updated-8-40-00-am-et-quotation-resumption-news-and-resumption-times"},"image":"https://cdn.brandfetch.io/BMBL/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"AAPG:1791895186975","url":"http://www.openbell.ai/news/AAPG:1791895186975","title":"Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35","content_text":"Citizens analyst Silvan Turkcan has initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating. A price target of $35 has been set for the company's stock.","summary":"Citizens analyst Silvan Turkcan has initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG) with a Market Outperform rating. A price target of $35 has been set for the company's stock.","date_published":"2026-10-13T12:39:46.975Z","date_modified":"2026-10-13T12:39:46.975Z","author":{"name":"Benzinga Newsdesk"},"tags":["Healthcare","AAPG","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Healthcare","ticker":"AAPG","original_url":"https://www.benzinga.com/news/26/10/62321725/citizens-initiates-coverage-ascentage-pharma-group-market-outperform-rating-announces-price-target-3"},"image":"https://cdn.brandfetch.io/AAPG/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"NRSN:1791895118988","url":"http://www.openbell.ai/news/NRSN:1791895118988","title":"NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027","content_text":"NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has scheduled a hearing with the Nasdaq Hearings Panel for November 10, 2026, following an appeal against a delisting determination. The company has regained compliance with Nasdaq's $1.00 minimum bid price requirement but still needs to address a deficiency regarding the $35 million minimum market value of listed securities. NeuroSense plans to present its strategy to meet compliance requirements at the hearing and has upcoming milestones for its PrimeC treatment, including a Health Canada submission in December 2026 and a decision on grant funding in Q1 2027.","summary":"NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has scheduled a hearing with the Nasdaq Hearings Panel for November 10, 2026, following an appeal against a delisting determination. The company has regained compliance with Nasdaq's $1.00 minimum bid price requirement but still needs to address a deficiency regarding the $35 million minimum market value of listed securities. NeuroSense plans to present its strategy to meet compliance requirements at the hearing and has upcoming milestones for its PrimeC treatment, including a Health Canada submission in December 2026 and a decision on grant funding in Q1 2027.","date_published":"2026-10-13T12:38:38.988Z","date_modified":"2026-10-13T12:38:38.988Z","author":{"name":"Benzinga Newsdesk"},"tags":["Healthcare","NRSN","AI Analysis","Impact: 60"],"_openbell":{"impact_score":60,"sector":"Healthcare","ticker":"NRSN","original_url":"https://www.benzinga.com/news/26/10/62321705/neurosense-therapeutics-announces-nasdaq-hearings-panel-date-november-10-minimum-bid-price-complianc"},"image":"https://cdn.brandfetch.io/NRSN/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"JPM:1791895065975","url":"http://www.openbell.ai/news/JPM:1791895065975","title":"JPMorgan CEO Jamie Dimon Sounds Alarm on Inflation, Rising Rates and Economic Risks","content_text":"JPMorgan Chase & Co. reported weaker-than-expected third-quarter results, with adjusted earnings of $5.75 per share, missing the consensus estimate of $5.90, and managed revenue rising 8% year over year to $50.91 billion, below expectations of $51.26 billion. The bank's net income increased 6% to $15.3 billion, impacted by $658 million in pretax investment securities losses. CEO Jamie Dimon highlighted economic risks including inflation and rising interest rates, while the bank raised its 2026 net interest income forecast to approximately $106.2 billion. JPMorgan's stock was down 0.39% to $333.00 in premarket trading.","summary":"JPMorgan Chase & Co. reported weaker-than-expected third-quarter results, with adjusted earnings of $5.75 per share, missing the consensus estimate of $5.90, and managed revenue rising 8% year over year to $50.91 billion, below expectations of $51.26 billion. The bank's net income increased 6% to $15.3 billion, impacted by $658 million in pretax investment securities losses. CEO Jamie Dimon highlighted economic risks including inflation and rising interest rates, while the bank raised its 2026 net interest income forecast to approximately $106.2 billion. JPMorgan's stock was down 0.39% to $333.00 in premarket trading.","date_published":"2026-10-13T12:37:45.975Z","date_modified":"2026-10-13T12:37:45.975Z","author":{"name":"Lekha Gupta"},"tags":["Financial Services","JPM","AI Analysis","Impact: -50"],"_openbell":{"impact_score":-50,"sector":"Financial Services","ticker":"JPM","original_url":"https://www.benzinga.com/markets/earnings/26/10/62321579/jpmorgan-ceo-jamie-dimon-sounds-alarm-on-inflation-rising-rates-and-economic-risks"},"image":"https://cdn.benzinga.com/files/images/story/2026/10/13/Closeup-Of-Jamie-Dimon--Ceo-Of-Jpmorgan-.jpg?width=250&height=187"},{"id":"FBDT:1791894994966","url":"http://www.openbell.ai/news/FBDT:1791894994966","title":"First Breach Announces Its Drone Prototype Completes Its First Autonomous Flight","content_text":"First Breach Inc. (NASDAQ: FBDT) has announced that its proprietary drone prototype has successfully completed its first autonomous flight. The company is focused on defense technologies, particularly in ammunition production and unmanned aerial systems, and is currently developing the flight software for the drone under a strategic agreement with Hellbender, Inc.","summary":"First Breach Inc. (NASDAQ: FBDT) has announced that its proprietary drone prototype has successfully completed its first autonomous flight. The company is focused on defense technologies, particularly in ammunition production and unmanned aerial systems, and is currently developing the flight software for the drone under a strategic agreement with Hellbender, Inc.","date_published":"2026-10-13T12:36:34.966Z","date_modified":"2026-10-13T12:36:34.966Z","author":{"name":"Benzinga Newsdesk"},"tags":["Industrials","FBDT","AI Analysis","Impact: 75"],"_openbell":{"impact_score":75,"sector":"Industrials","ticker":"FBDT","original_url":"https://www.benzinga.com/news/26/10/62321546/first-breach-announces-its-drone-prototype-completes-its-first-autonomous-flight"},"image":"https://cdn.brandfetch.io/FBDT/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"BORR:1791894945937","url":"http://www.openbell.ai/news/BORR:1791894945937","title":"Borr Drilling Director Tor Olav Troim Purchases 2.5M Shares At Average Price Of $4.74/Share, Increasing Indirect Holdings To 37.3M Shares","content_text":"Borr Drilling's Director, Tor Olav Troim, has acquired 2.5 million shares at an average price of $4.74 per share, as reported in a recent SEC filing. This purchase raises his indirect holdings in the company to a total of 37.3 million shares.","summary":"Borr Drilling's Director, Tor Olav Troim, has acquired 2.5 million shares at an average price of $4.74 per share, as reported in a recent SEC filing. This purchase raises his indirect holdings in the company to a total of 37.3 million shares.","date_published":"2026-10-13T12:35:45.937Z","date_modified":"2026-10-13T12:35:45.937Z","author":{"name":"Benzinga Newsdesk"},"tags":["Energy","BORR","AI Analysis","Impact: 50"],"_openbell":{"impact_score":50,"sector":"Energy","ticker":"BORR","original_url":"https://www.benzinga.com/news/26/10/62321509/borr-drilling-director-tor-olav-troim-purchases-2-5m-shares-average-price-4-74-share-increasing-indi"},"image":"https://cdn.brandfetch.io/BORR/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"AZIO:1791894926569","url":"http://www.openbell.ai/news/AZIO:1791894926569","title":"AZIO AI Secures First Atlas One Customer With Hosting Agreement For Up To 50 MW Capacity","content_text":"AZIO AI Holdings Inc. has signed its first hosting agreement for the Atlas One project with Power Champion Investment Limited, covering an initial capacity of 10 megawatts and expansion rights up to 50 megawatts. This agreement marks the first contracted customer for Atlas One and positions AZIO AI alongside leading technology and infrastructure providers in the AI sector.","summary":"AZIO AI Holdings Inc. has signed its first hosting agreement for the Atlas One project with Power Champion Investment Limited, covering an initial capacity of 10 megawatts and expansion rights up to 50 megawatts. This agreement marks the first contracted customer for Atlas One and positions AZIO AI alongside leading technology and infrastructure providers in the AI sector.","date_published":"2026-10-13T12:35:26.569Z","date_modified":"2026-10-13T12:35:26.569Z","author":{"name":"Benzinga Newsdesk"},"tags":["Technology","AZIO","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Technology","ticker":"AZIO","original_url":"https://www.benzinga.com/news/26/10/62321473/azio-ai-secures-first-atlas-one-customer-hosting-agreement-50-mw-capacity"},"image":"https://cdn.brandfetch.io/AZIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"DXF:1791894925727","url":"http://www.openbell.ai/news/DXF:1791894925727","title":"Eason Technology Regains NYSE American Compliance","content_text":"Eason Technology Limited (NYSE American: DXF) announced on October 8, 2026, that it has regained compliance with NYSE American listing standards. The company resolved a previous deficiency related to Section 1003(a)(ii) of the Company Guide by demonstrating compliance for two consecutive quarters. This follows communications from the Exchange regarding its listing status in late 2025.","summary":"Eason Technology Limited (NYSE American: DXF) announced on October 8, 2026, that it has regained compliance with NYSE American listing standards. The company resolved a previous deficiency related to Section 1003(a)(ii) of the Company Guide by demonstrating compliance for two consecutive quarters. This follows communications from the Exchange regarding its listing status in late 2025.","date_published":"2026-10-13T12:35:25.727Z","date_modified":"2026-10-13T12:35:25.727Z","author":{"name":"Benzinga Newsdesk"},"tags":["Financial Services","DXF","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Financial Services","ticker":"DXF","original_url":"https://www.benzinga.com/news/26/10/62321465/eason-technology-regains-nyse-american-compliance"},"image":"https://cdn.brandfetch.io/DXF/w/400/h/400?c=1idopYfmtR7ZKg8QMud"},{"id":"SPY:1791894913470","url":"http://www.openbell.ai/news/SPY:1791894913470","title":"S&P 500 Above 8,000? Fidelity’s Timmer Sees Q3 Earnings and Seasonal Tailwinds Powering Bull Market","content_text":"Jurrien Timmer, Fidelity Investments' director of Global Macro, suggests that the S&P 500 index could surpass 8,000 due to strong corporate earnings momentum and seasonal factors as the bull market marks its fourth anniversary. The index has increased 113% since its low on October 13, 2022, with Q3 earnings expected to show a growth rate of 25%, potentially reaching 30-35%. Despite tightening financial conditions, corporate profit margins have reached a historic peak of 17.4%. Year-to-date, the S&P 500 is up 13.83%, with mixed performance in ETFs tracking major indices.","summary":"Jurrien Timmer, Fidelity Investments' director of Global Macro, suggests that the S&P 500 index could surpass 8,000 due to strong corporate earnings momentum and seasonal factors as the bull market marks its fourth anniversary. The index has increased 113% since its low on October 13, 2022, with Q3 earnings expected to show a growth rate of 25%, potentially reaching 30-35%. Despite tightening financial conditions, corporate profit margins have reached a historic peak of 17.4%. Year-to-date, the S&P 500 is up 13.83%, with mixed performance in ETFs tracking major indices.","date_published":"2026-10-13T12:35:13.470Z","date_modified":"2026-10-13T12:35:13.470Z","author":{"name":"Rishabh Mishra"},"tags":["Financial Services","SPY","AI Analysis","Impact: 75"],"_openbell":{"impact_score":75,"sector":"Financial Services","ticker":"SPY","original_url":"https://www.benzinga.com/markets/market-summary/26/10/62321461/sp-500-above-8000-fidelitys-timmer-sees-q3-earnings-and-seasonal-tailwinds-powering-bull-market"},"image":"https://cdn.benzinga.com/files/images/story/2026/10/13/Tallinn--Estonia---August-4th-2023---Com.jpg?width=250&height=187"},{"id":"BDRX:1791894898634","url":"http://www.openbell.ai/news/BDRX:1791894898634","title":"Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly","content_text":"Biodexa Pharmaceuticals PLC has enrolled 100 patients in its Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with recruitment occurring at 29 clinical sites across the U.S., Canada, and Europe. The trial is set to initiate shortly, with a pre-specified futility analysis planned after 25 Progression Free Survival (PFS) events and a database lock after 75 PFS events.","summary":"Biodexa Pharmaceuticals PLC has enrolled 100 patients in its Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with recruitment occurring at 29 clinical sites across the U.S., Canada, and Europe. The trial is set to initiate shortly, with a pre-specified futility analysis planned after 25 Progression Free Survival (PFS) events and a database lock after 75 PFS events.","date_published":"2026-10-13T12:34:58.634Z","date_modified":"2026-10-13T12:34:58.634Z","author":{"name":"Benzinga Newsdesk"},"tags":["Healthcare","BDRX","AI Analysis","Impact: 70"],"_openbell":{"impact_score":70,"sector":"Healthcare","ticker":"BDRX","original_url":"https://www.benzinga.com/news/26/10/62321445/biodexa-pharmaceuticals-enrolls-100-patients-its-registrational-phase-3-serenta-trial-erapa-familial"},"image":"https://cdn.brandfetch.io/BDRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud"}]}